Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9655 Maroon Circle ENGLEWOOD CO 80112 |
Tel: | N/A |
Website: | https://www.zynex.com |
IR: | See website |
Key People | ||
Thomas Sandgaard Chairman of the Board, President, Chief Executive Officer | Daniel J. Moorhead Chief Financial Officer | Anna Lucsok Chief Operating Officer |
Business Overview |
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Company's devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company's products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter. |
Financial Overview |
For the fiscal year ended 31 December 2023, Zynex Inc revenues increased 17% to $184.3M. Net income decreased 43% to $9.7M. Revenues reflect Devices increase of 35% to $58.8M, Supplies increase of 9% to $125.5M. Net income was offset by Sales and Marketing - Balancing value increase of 32% to $83.4M (expense), General and administrative - Balancing increase of 40% to $36.6M (expense), Research and Development in SGA increase of 30% to $9.2M (expense). |
Employees: | 1,100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $401.62M as of Dec 31, 2023 |
Annual revenue (TTM): | $184.32M as of Dec 31, 2023 |
EBITDA (TTM): | $15.00M as of Dec 31, 2023 |
Net annual income (TTM): | $9.73M as of Dec 31, 2023 |
Free cash flow (TTM): | $16.55M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $13.68M as of Dec 31, 2023 |
Shares outstanding: | 31,929,682 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |